Home > Boards > US Listed > Medical - Equipment > Cytosorbents Corporation (CTSO)

Recent Maxim analyst report with $14 12 month

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
ranchhand71 Member Profile
 
Followed By 5
Posts 695
Boards Moderated 0
Alias Born 12/22/17
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/2/2021 6:01:59 AM
CytoSorbents Appoints Terri Anne Powers, IRC as Vice President of Investor Relations and Corporate Communications PR Newswire (US) - 6/1/2021 7:08:00 AM
CytoSorbents to Present at the Jefferies Virtual Healthcare Conference PR Newswire (US) - 5/27/2021 7:00:00 AM
CytoSorbents' CytoSorb blood purification now available in Singapore Seeking Alpha - 5/25/2021 7:51:17 AM
CytoSorb® Registered and Commercially Available in Singapore PR Newswire (US) - 5/25/2021 7:08:00 AM
CytoSorbents to Present at the UBS Global Healthcare Virtual Conference and Oppenheimer MedTech, Tools and Diagnostic Summit PR Newswire (US) - 5/19/2021 7:00:00 AM
CytoSorbents awarded $1.5M U.S army research and development contract Seeking Alpha - 5/11/2021 9:08:14 AM
CytoSorbents Awarded $1.5 Million Sequential Phase II SBIR Contract to Advance the Treatment of Severe Hyperkalemia in Trauma... PR Newswire (US) - 5/11/2021 8:50:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/5/2021 6:07:06 AM
Cytosorbents EPS misses by $0.05, misses on revenue Seeking Alpha - 5/4/2021 4:33:48 PM
CytoSorbents Reports First Quarter 2021 Financial and Operational Results PR Newswire (US) - 5/4/2021 4:15:00 PM
CytoSorbents to Report Q1 2021 Operating and Financial Results PR Newswire (US) - 4/27/2021 1:55:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/20/2021 4:31:57 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/19/2021 4:31:35 PM
FDA gives green light to CytoSorbents to begin U.S. STAR-T trial for ticagrelor removal Seeking Alpha - 4/19/2021 7:48:55 AM
U.S. FDA Approves CytoSorbents to Initiate U.S. STAR-T Trial For Ticagrelor Removal During Cardiothoracic Surgery PR Newswire (US) - 4/19/2021 7:08:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/15/2021 7:48:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/31/2021 4:21:49 PM
CytoSorbents Announces Lease of New Global Headquarters in Princeton, New Jersey PR Newswire (US) - 3/29/2021 7:08:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/17/2021 4:31:50 PM
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for U.S. Trial on Ticagrelor Removal During Cardio... PR Newswire (US) - 3/16/2021 3:15:00 PM
CytoSorbents to Present at the Oppenheimer 31st Annual Healthcare Conference PR Newswire (US) - 3/12/2021 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/9/2021 4:31:25 PM
Cytosorbents EPS beats by $0.03, beats on revenue Seeking Alpha - 3/9/2021 4:21:39 PM
CytoSorbents Announces 2020 Financial and Operational Results PR Newswire (US) - 3/9/2021 4:15:00 PM
ranchhand71   Thursday, 05/13/21 10:17:16 AM
Re: None
Post # of 26389 
Recent Maxim analyst report with $14 12 month target price.
2021 Revenues Est $50,299,000
2022 Revenues Est $70,000,000
Also show revenues greater than expenses for first time in Q1 2022!
Other comments:

CytoSorbents reported 1Q21 results on 5/4, post-close with product sales of
$10.6M, down 12% from 4Q20 and up 24% y/y. The company reported a net
loss of ($0.4M) and ended the period with $68.5M in cash on the balance sheet.
• The pullback was based on COVID restrictions in Europe, combined with a trough in cases reducing COVID sales. That said, the overall base business performed well vs. prior quarters.
• Clinical programs are making progress. REFRESH 2-AKI has resumed
enrollment and data is expected from the CTC Registry study of CytoSorb inCOVID-19 and the REMOVE endocarditis study in mid-2020. The CYTATION Study has also begun enrolling patients in Germany.
• Conclusion.
Over 2021, we expect COVID-19 revenues to continue to support
topline. As lockdown restrictions ease, CytoSorbents should be able to fullyleverage its approval in removal of blood thinners to drive growth in its base
business.


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences